Ketamine for Obsessive Compulsive Disorder

 

Ketamine for Obsessive Compulsive Disorder(OCD) Summary

Ketamine has been recognized as a rapid-acting intervention for treatment-resistant Obsessive-Compulsive Disorder (OCD) giving much needed relief to patients who have not responded to standard (SSRIs) or Cognitive-Behavioral Therapy. Ketamine targets the cortico-striatal-thalamo-cortical circuit, which is often overactive in OCD patients, essentially "resetting" rigid neural pathways that drive obsessive thoughts. By blocking NMDA receptors and increasing glutamate levels, ketamine promotes the growth of new synaptic connections, making the brain more flexible and adaptable to new ways of thinking. Studies suggest that Ketamine normalizes activity in the dorsal anterior cingulate cortex (dACC), the brain region responsible for shifting focus between thoughts and actions. Clinical trials show that a single low-dose IV infusion can lead to a 30–50% reduction in symptoms within one to two hours of treatment. For OCD treatment, results are transient, with a single infusion effects lasting only 1-7 days. Sustaining the treatment requires a series of sessions often twice weekly for 3-4 weeks.

Note: Ketamine has not yet officially been approved for treating OCD by the FDA, so its use is considered "off-label" and should only be done under supervision of a physician.

1) Mechanism of Action

Ketamine is used as a rapid-acting option for OCD, especially treatment-resistant OCD.

  • NMDA receptor antagonism affecting glutamate transmission
  • Relative increase in AMPA receptor signaling
  • Activation of BDNF and mTOR pathways
  • Enhanced synaptic plasticity in fronto-striatal circuits

OCD is linked to dysregulation of cortico-striato-thalamo-cortical (CSTC) circuits, and ketamine helps modulate networks involved in intrusive thoughts and compulsive behaviors.

2) Clinical Indications

  • Treatment-resistant OCD
  • Severe OCD with significant functional impairment
  • Failure of standard therapies (SSRIs and ERP therapy)
  • Note: Use of Ketamine for OCD is off-label and requires monitoring by a physician
Note: Evidence is still emerging; and use remains largely off-label under supervision of a physician.

3) Clinical Effects

  • Reduced intensity of obsessions
  • Decreased compulsive urges
  • Improved cognitive flexibility
  • Temporary reduction in anxiety linked to obsessions
  • Timeline: Noticeable Results - within hours, Peak Results - ~1-3 days, Total Duration about a week for most.
  • Note: Since effects are often temporary, protocols usually involved repeated dosing sessions

4) Methods of Administration

Typically administered in controlled clinical settings.

  • Intravenous ketamine infusion(IV)
  • Intranasal formulations in some clinical programs

Treatment is often paired with ongoing psychiatric care and may be combined with ERP therapy.

5) Potential Advantages

  • Rapid onset of symptom relief
  • Possible benefit in treatment-resistant OCD
  • May enhance learning and engagement during behavioral therapy (ERP)

6) Limitations and Risks

  • Short duration of benefit
  • Optimal dosing strategies remain unclear
  • Potential risk of misuse or dependence

7) Adverse Effects

Common acute effects (often resolving within 1–2 hours):

  • Dissociation
  • Perceptual disturbances
  • Dizziness
  • Nausea
  • Sedation
  • Transient increases in blood pressure

8) Current Clinical Role

Ketamine is considered only in research settings or specialized programs when there is:

  • Severe, treatment-resistant OCD
  • Failure of multiple medications
  • Failure of ERP therapy